These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24598449)

  • 41. Functional and structural characteristics of NY-ESO-1-related HLA A2-restricted epitopes and the design of a novel immunogenic analogue.
    Webb AI; Dunstone MA; Chen W; Aguilar MI; Chen Q; Jackson H; Chang L; Kjer-Nielsen L; Beddoe T; McCluskey J; Rossjohn J; Purcell AW
    J Biol Chem; 2004 May; 279(22):23438-46. PubMed ID: 15004033
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
    Ishihara M; Nishida Y; Kitano S; Kawai A; Muraoka D; Momose F; Harada N; Miyahara Y; Seo N; Hattori H; Takada K; Emori M; Kakunaga S; Endo M; Matsumoto Y; Sasada T; Sato E; Yamada T; Matsumine A; Nagata Y; Watanabe T; Kageyama S; Shiku H
    Int J Cancer; 2023 Jun; 152(12):2554-2566. PubMed ID: 36727538
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.
    Zeng G; Wang X; Robbins PF; Rosenberg SA; Wang RF
    Proc Natl Acad Sci U S A; 2001 Mar; 98(7):3964-9. PubMed ID: 11259659
    [TBL] [Abstract][Full Text] [Related]  

  • 45. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
    Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
    J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
    Held G; Matsuo M; Epel M; Gnjatic S; Ritter G; Lee SY; Tai TY; Cohen CJ; Old LJ; Pfreundschuh M; Reiter Y; Hoogenboom HR; Renner C
    Eur J Immunol; 2004 Oct; 34(10):2919-29. PubMed ID: 15368308
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A combination of exosomes carrying TSA derived from HLA-A2-positive human white buffy coat and polyI:C for use as a subcellular antitumor vaccination.
    Ren WN; Chang CK; Fan HH; Guo F; Ren YN; Yang J; Guo J; Li X
    J Immunoassay Immunochem; 2011; 32(3):207-18. PubMed ID: 21574092
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials.
    Davis JL; Theoret MR; Zheng Z; Lamers CH; Rosenberg SA; Morgan RA
    Clin Cancer Res; 2010 Dec; 16(23):5852-61. PubMed ID: 21138872
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combining SiRPα decoy-coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells.
    Stefanidis E; Semilietof A; Pujol J; Seijo B; Scholten K; Zoete V; Michielin O; Sandaltzopoulos R; Coukos G; Irving M
    J Clin Invest; 2024 Apr; 134(11):. PubMed ID: 38828721
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.
    Klippel ZK; Chou J; Towlerton AM; Voong LN; Robbins P; Bensinger WI; Warren EH
    Gene Ther; 2014 Mar; 21(3):337-42. PubMed ID: 24451117
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
    Chinnasamy N; Wargo JA; Yu Z; Rao M; Frankel TL; Riley JP; Hong JJ; Parkhurst MR; Feldman SA; Schrump DS; Restifo NP; Robbins PF; Rosenberg SA; Morgan RA
    J Immunol; 2011 Jan; 186(2):685-96. PubMed ID: 21149604
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
    Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
    Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.
    Hughes MS; Yu YY; Dudley ME; Zheng Z; Robbins PF; Li Y; Wunderlich J; Hawley RG; Moayeri M; Rosenberg SA; Morgan RA
    Hum Gene Ther; 2005 Apr; 16(4):457-72. PubMed ID: 15871677
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.
    Karbach J; Pauligk C; Bender A; Gnjatic S; Franzmann K; Wahle C; Jäger D; Knuth A; Old LJ; Jäger E
    Int J Cancer; 2006 Feb; 118(3):668-74. PubMed ID: 16152624
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer.
    Chou J; Voong LN; Mortales CL; Towlerton AM; Pollack SM; Chen X; Yee C; Robbins PF; Warren EH
    J Immunother; 2012; 35(2):131-41. PubMed ID: 22306901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.
    Pollack SM; Jungbluth AA; Hoch BL; Farrar EA; Bleakley M; Schneider DJ; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
    Cancer; 2012 Sep; 118(18):4564-70. PubMed ID: 22359263
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules.
    Bethune MT; Li XH; Yu J; McLaughlin J; Cheng D; Mathis C; Moreno BH; Woods K; Knights AJ; Garcia-Diaz A; Wong S; Hu-Lieskovan S; Puig-Saus C; Cebon J; Ribas A; Yang L; Witte ON; Baltimore D
    Proc Natl Acad Sci U S A; 2018 Nov; 115(45):E10702-E10711. PubMed ID: 30348802
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype.
    Kang S; Wang L; Xu L; Wang R; Kang Q; Gao X; Yu L
    Oncogene; 2022 Oct; 41(42):4696-4708. PubMed ID: 36097193
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Immune effects of specific CTLs response induced by dendritic cells pulsed with NY-ESO-1 peptide].
    Liu JW; Lu X; Yang ZM; Deng LJ; Yang L
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 49(5):840-846. PubMed ID: 29045966
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
    Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
    Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.